Xience prime xpedition

The experimental stent (Orsiro, Biotronik AG, Bülach, Switzerland) consisted of an ultrathin-strut (60 μm) for stent diameters ≤3.0 mm and a thin-strut (80 μm) for stent diameters >3.0 mm cobalt-chromium L-605 metallic stent platform covered by an amorphous, hydrogen-rich, silicon-carbide passive layer (PROBIO), and an asymmetrical biodegradable poly-l-lactic acid polymer active coating releasing sirolimus at a dose of 1.4 μg per mm 2 stent surface over a period of 12 to 14 weeks (BIOLUTE). 6 (link) The polymer matrix is degraded within 12 to 24 months. 6 (link) The control stent (Xience Prime/ Xpedition, Abbott Vascular, Abbott Park, IL) consisted of a thin-strut (81 μm across all range of stent diameters) cobaltchromium stent platform releasing everolimus from a durable poly-n-butyl-methacrylate and vinylidene fluoride and hexafluoropropylene copolymer.
Randomization was performed using a web-based system and stratified according to the center and to the presence or absence of ST-segment-elevation myocardial infarction. PCI was performed in accordance with guidelines current at the time of enrollment. Intraprocedural medications included

Patients who underwent PCI at Bern University Hospital, Switzerland, were prospectively and consecutively enrolled in the CARDIOBASE Bern PCI Registry. There were no formal patient and lesion exclusion criteria, and all patients who provided informed consent were consecutively enrolled in the registry. In the present analysis, we included exclusively patients treated with ultrathin strut (ϕ 2.25-3.0 mm: 60 µm and ϕ 3.5-4.0 mm: 80 µm) BP-SES (Orsiro, Biotronik AG, Bülach, Switzerland) or thin strut (81 µm) DP-EES (Xience Prime/Xpedition, Abbott Vascular, Abbott Park, IL) and excluded patients who received a different stent type. At Bern University Hospital cathlab, stent types used for PCI are alternated on a daily basis (7 days a week) among the available device types (ie, size and length) independent of scheduled operators, patients, and lesions with the intention to reduce selection bias.
The study complied with the Declaration of Helsinki and was approved by the institutional ethics committee at Bern University Hospital, Switzerland. The registry was registered. The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure.